Fisheries and Aquatic Sciences
BioMed Central
Research Article

The antihyperlipidemic effect of alginate-free residue from sea tangle in hyperlipidemic rats

Mi-Jin Yim1, Jeong Min Lee1, Grace Choi1, Soon-Yeong Cho2, Dae-Sung Lee1,*http://orcid.org/0000-0003-0627-1402
1National Marine Biodiversity Institute of Korea (MABIK)325-902SeocheonChungcheongnam-doRepublic of Korea
2Department of Food Processing and DistributionGangneung-Wonju National University210-70225457GangneungRepublic of Korea
*82-41-950-0767daesung@mabik.re.kr

© The Author(s) 2019. Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Received: Sep 27, 2019; Accepted: Nov 12, 2019

Published Online: Nov 27, 2019

Abstract

Background

In order to assess the high value-added use of the alginate-free residue of sea tangle, an animal study was performed to evaluate the functional activities and key compounds present. In the animal study, sea tangle and the alginate-free residue demonstrated good anti-hyperlipidemic and anti-arteriosclerotic abilities.

Results

The functional compounds in the alginate-free residue of the sea tangle were effectively extracted by supercritical fluid extraction (SFE). The optimum extraction temperature and pressure were 40 °C and 6500 psi (M1) in the SFE, a better method in comparison to the conditions of 70 °C and 4500 psi (M2), respectively. The anti-atherosclerotic effects of the alginate-free residue of sea tangle (M1, M2) were investigated in Sprague-Dawley rats treated with poloxamer 407, Triton WR 1339, corn oil, and a high-fat diet. The M1 fraction reduced the serum lipid levels with greater efficacy than the M2 fraction. In the hyperlipidemic rats, treatment with M1 decreased the serum triglyceride (TG), total cholesterol (TC), and low-density lipoprotein-cholesterol (LDL-C) levels when compared to the levels in normal rats.

Conclusion

Our results demonstrated that the alginate-free residue of sea tangle reduces serum TC, TG, and LDL-C. These results suggest that the alginate-free residue of sea tangle contains physiologically active components, such as fucosterol, that may exert beneficial effects in the prevention of atherosclerosis.

Keywords: Antihyperlipidemic; Fucosterol; Saccharina japonica; Sea tangle

Background

A number of seaweed species are consumed as food in several countries and documented as drugs in traditional Chinese medicine. Fucoidan extracted from L. japonica is an antioxidant, with the fatty acid composition of n–3 fatty acids, polysaccharides, vitamins, minerals and trace elements (Jeong et al., 1993), and minor compounds such as sterols. Saccharina japonica is also well known for several biological activities, including antioxidant, anti-mutagenic, and antibacterial activities (Okai et al., 1993; Wang et al., 2006; Park et al., 2009).

Recently, many studies have reported on prospective natural resources regulating the serum cholesterol and triglyceride (TG) levels (Ghule et al., 2006; Lemhadri et al., 2006). Hypercholesterolemia and hyperlipidemia are important risk factors in the initiation and progression of atherosclerotic disease (Goldstein et al., 1973; Harrison et al., 2003). Hypercholesterolemia is characterized by an increase in serum lipids such as TC, low-density lipoprotein cholesterol (LDL-C), and TG (Levine et al., 1995). Hyperlipidemia mainly demonstrates increased levels of total cholesterol (TC), TG, and LDL-C, along with a decrease in the high-density lipoprotein-cholesterol (HDL-C). Studies have indicated the potential of synthetic and natural sources that could regulate plasma TC and TG levels in coronary atherosclerosis (Ghule et al., 2009).

The sea tangle is often used as a functional food or alginate extraction material in Korea and Japan. The alginate-free residue of sea tangle is discarded as waste. For the purpose of high value-added use of the alginate-free residue of sea tangle, we investigated the anti-hyperlipidemic and anti-atherosclerotic effects of the alginate-free residue from sea tangle.

Methods

Materials and chemicals

The sea tangle (Saccharina japonica) was obtained from a local supplier (Gangneung, Gangwon-do, Korea) in March 2007. Poloxamer-407 (Pluronic F-127) and corn oil were purchased from Sigma (St. Louis, MO, USA). TC (Cholestezyme-V), TG (Triglyzyme-V), and high-density lipoprotein-cholesterol (HDL-C; HDL-C555) were assayed using commercially available kits (Asan Pharm. Co., Ltd., Korea).

Preparation of samples

The functional compounds (M1 and M2) in the alginate-free residue of sea tangle were effectively extracted by supercritical fluid extraction (SFX 3560, Lincoln, USA). Supercritical CO2 was used as a solvent and extraction was performed using 1.0 g sea tangle in a 10-mL extractor. The extraction was performed for 20 min with a fluid flow rate of 1.0 mL/min, measured at the pump head. The extraction was performed at 40 °C and 6500 psi in the sample cartridge for 10 min, followed by extraction through the cartridge at 70 °C. The extracted sample was collected in collection vial with ethanol.

Animals and treatments

Sprague-Dawley male rats weighing 130–150 g were obtained from the Dae-han Biolink Co., Ltd. (Chungbuk, Republic of Korea), maintained under constant conditions (temperature 20 ± 2 °C, humidity 40–60%, light 12-h cycle) and acclimatized for 1 week. The rats had free access to drinking water, with the feed prepared according to the recommendations of the American Institute of Nutrition (AIN-76). After the animals were fed the AIN-76 diets, 50 or 100 mg (lipid solution/kg of body weight in 5% Tween 80) of the alginate-free residue extracted from sea tangle powder was orally administered, once a day for 2 weeks. Following this period, the rats were fasted for 24 h and killed and dissected under CO2 anesthesia. All animal experiments were approved by the University of Kyungsung Animal Care and Use Committee.

Experimental procedures

The poloxamer-407 hyperlipidemic diet model was determined according to the method described by Wout et al. (1992). The rats were administered a 300 mg/kg dose of poloxamer 407 intraperitoneally, prepared by combining the agent with saline solution.

The Triton WR-1339 hyperlipidemic diet model was performed according to the method described by Kusama et al. (1998). Triton WR-1339 (200 mg/kg) was injected into the tail vein after a fasting period of 16 h. After inducing hyperlipidemia, the animals were anesthetized with the CO2 gas and blood was gathered for analysis 18 h later.

According to Duhault et al. (1976), we administered corn oil in the diet at 3 g/kg. The compositions of the normal and high-fat diet are shown in Table 1. The high-fat-diet–treated rats were orally administered the test substance for the last week, with the high-fat diets fed daily for 6 weeks.

Table 1. Composition of the normal and high-fat diet (Unit: g/100 g)

Ingredients

Normal diet

High-fat diet

Casein

20

29

Corn starch

60

10

Sugar

0.0

10

Lard

0.0

35

Corn oil

9.0

5.0

Cellulose

5.0

5.0

AIN76 mineral mixture

3.5

3.5

AIN76 vitamin mixture

1.0

1.0

Cholesterol

1.0

1.0

DL-methionine

0.3

0.3

Choline

0.2

0.2

AIN76 mixture: Nutritional Biochemicals, ICN Life Science Group, Cleveland, Ohio

Download Excel Table

Extraction of feces lipids

Based on the method of Folch et al. (1957), the lipids were extracted by homogenization of the feces with 2:1 chloroform-methanol (v/v), followed by centrifugation. The lipids were extracted based on the dry weight of the feces and assayed for TC and TG concentration using a standard enzymatic assay kit (Asan Pharm., Korea).

Glucose analysis

The levels of TG, TC, and HDL-C were determined by enzymatic colorimetric methods using commercial kits (Shinyang Chemical Co., Busan, Korea). The concentration of LDL-C was calculated using the following equation (Friedwald et al., 1972).

LDL-C = TC–HDL-C–(TG/5)

Identification of M1 with HPLC

High-performance liquid chromatograph (HPLC, Hitachi, Tokyo, Japan) system was performed using a Lichrospher RP-18e column (8 × 250 mm, Merck). The mobile phase used was methanol/acetonitrile (7:3, v/v) at a flow rate of 1.0 mL/min, and detection was performed at 450 nm and 210 nm by a diode array detector (L7455 type, Hitachi). The amounts of M1 fractions were quantified from their peak area by the use of a standard curve identified with fucosterol.

Statistical analysis

All results are presented as the mean ± SD. Data were evaluated by one-way ANOVA using SPSS (IBM SPSS, Armonk, NY, USA), after which the differences between the means values were assessed using Duncan’s multiple range test. Results were considered statistically significant at P < 0.05.

Results

The effect of M1 and M2 on poloxamer 407-induced hyperlipidemia

We assessed the effect of the oral administration of M1 and M2 100 mg/kg of body weight, once a day for 2 weeks, on the serum lipid levels in poloxamer 407-induced hyperlipidemic rats. Serum TG and TC levels were reduced by M1 and M2 when compared to the control rats, in poloxamer 407-induced hyperlipidemic rats (Table 2). M1 demonstrated a more potent effect on the serum lipid levels than the M2 fraction. Hence, we proceeded to assess if M1 possessed a dose-dependent effect. The administration of the M1 at a dose of 50 and 100 mg/kg body weight significantly reduced serum lipid levels when compared to the control rats (Table 3).

Table 2. Effect of M1and M2 on the serum lipid levels in poloxamer-407 injected rats

Treatment

Dose

Triglyceride

Total cholesterol

mg/kg

mg/dL

Normal

80.6 ± 8.46d

66.5 ± 9.49c

Poloxamer-407

1101.6 ± 63.7a

770.3 ± 48.8a

M1

100

881.3 ± 52.2c

620.9 ± 33.6b

M2

100

996.5 ± 70.3b

728.6 ± 43.1a

Values represent mean ± S.D. (n = 8). Values sharing the same column superscript letter are not significantly different from each other (P < 0.05) by Duncan’s multiple range test

Download Excel Table
Table 3. Effect of M1 on the serum lipid levels in poloxamer-407 treated rats

Treatment

Dose

Triglyceride

Total cholesterol

mg/kg

mg/dL

Normal

81.7 ± 9.53d

69.8 ± 8.56c

Poloxamer-407

1207.8 ± 100.5a

800.6 ± 50.4a

M1

50

937.5 ± 87.9b

740.6 ± 47.8a

100

741.6 ± 94.7c

531.2 ± 63.2a

Values represent mean ± S.D. (n=9). Values sharing the same column superscript letter are not significantly different from each other (P < 0.05) by Duncan’s multiple range test

Download Excel Table

The effect of M1 on Triton WR 1339-induced hyperlipidemia

Rats with hyperlipidemia induced by Triton WR 1339 demonstrated remarkably high serum levels of TG, TC, and LDL-C. However, the administration of the M1 at doses of 50 and 100 mg/kg body weight significantly reduced the TG levels in the hyperlipidemic rats as compared to the control rats (Table 4). The TC and LDL-C were reduced in the M1-treated groups compared with control rats; however, no dose-dependent differences were observed between M1 and M2.

Table 4. Effect of M1 on the serum triglyceride, total cholesterol and low-density lipoprotein-cholesterol (LDL-C) levels in Triton WR 1339-induced hyperlipidemic rats

Treatment

Dose

Triglyceride

Total cholesterol

LDL-C

mg/kg

mg/dL

Normal

98.4 ± 15.9d

79.6 ± 9.36c

18.2 ± 2.43c

Control

736.5 ± 30.8a

191.4 ± 14.5a

67.3 ± 8.57a

M1

50

639.5 ± 45.7b

167.0 ± 10.8b

53.7 ± 4.53b

100

424.8 ± 38.5c

150.9 ± 7.53b

49.0 ± 5.07b

Values represent mean ± S.D. (n=9). Values sharing the same column superscript letter are not significantly different from each other (P < 0.05) by Duncan’s multiple range test

Download Excel Table

The effect of M1 on 30% corn oil-induced hyperlipidemia

Table 5 shows the serum lipid levels following the oral administration of M1 50 and 100 mg/kg body weight. The serum lipid levels such as TG and TC were remarkably increased in the control rats induced corn oil; however, the administration of M1 significantly reduced the serum TG and TC levels.

Table 5. Effect of M1 on the serum triglyceride and total cholesterol levels in 30% corn oil-induced hyperlipidemic rats

Treatment

Dose

Triglyceride

Total cholesterol

mg/kg

mg/dL

Normal

86.8 ± 10.5c

73.5 ± 8.56c

Control

230.7 ± 19.7a

98.8 ± 7.79a

M1

50

197.6 ± 20.3b

91.6 ± 9.66a

100

172.9 ± 11.1b

86.7 ± 5.24b

Values represent mean ± S.D. (n=9). Values sharing the same column superscript letter are not significantly different from each other (P < 0.05) by Duncan’s multiple range test

Download Excel Table

The effect of M1 on high fat diet-induced hyperlipidemia

The effects of M1 on the serum lipid levels of rats fed a high-fat diet are shown in Table 6. The rats fed a high-fat diet reported significantly increased levels of serum of TG, TC, and LDL-C compared to the normal rats. The serum lipid levels including TG, TC, and LDL-C were significantly reduced by M1 100 mg/kg, with no reduction observed in the serum lipid levels of the control rats (Table 6). The abdominal fat pad weights in the normal and diet-induced obesity rats fed with M1 were also assessed. The weights of the retroperitoneal WAT, epididymal WAT, and total abdominal WAT per body weight of rats were significantly lower in the diet-induced obesity rats treated with M1 100 mg/kg body weight than the control rats (Table 7). The fecal contents of the diet-induced obesity rats were not altered when compared to dose-dependent of M1. The rats fed the M1 100 mg/kg of body weight diet decreased of total lipid, TG and TC (Table 8). The rats fed M1 100 mg/kg reported lower blood leptin and insulin levels than the control rats (Table 9).

Table 6. Serum lipid contents of the normal and diet-induced obesity rats fed with M1 for 2 weeks

Treatment

Dose

Triglyceride

Total cholesterol

LDL-C

mg/kg

mg/dL

Normal

76.9 ± 4.80c

66.9 ± 4.57c

20.6 ± 4.26c

Control

121.3 ± 11.3a

119.0 ± 3.56a

76.5 ± 10.5a

M1

50

111.6 ± 9.53a,b

115.2 ± 5.27a

65.2 ± 5.28a

100

97.7 ± 5.23b

106.3 ± 3.11b

51.4 ± 3.26b

Values represent mean ± S.D. (n=9). Values sharing the same column superscript letter are not significantly different from each other (P < 0.05) by Duncan’s multiple range test

Download Excel Table
Table 7. Abdominal fat pad weights in the normal and diet-induced obesity rats fed with M1 for 2 weeks

Treatment

Dose

Retroperitoneal

Epididymal

Total abdominal

mg/kg

g

Normal

6.44 ± 0.37c

7.82 ± 0.46c

14.26 ± 0.97c

Control

10.58 ± 0.83a

12.06 ± 0.53a

22.56 ± 1.54a

M1

50

9.53 ± 0.46a,b

11.17 ± 0.50a,b

20.70 ± 0.86a,b

100

8.69 ± 0.50b

10.53 ± 0.49b

19.22 ± 0.95b

Values represent mean ± S.D. (n=9). Values sharing the same column superscript letter are not significantly different from each other (P < 0.05) by Duncan’s multiple range test

Download Excel Table
Table 8. Feces lipid contents of the normal and diet-induced obesity rats fed with M1 for 2 weeks

Treatment

Dose

Dry weight

Total lipid

Triglyceride

Total cholesterol

mg/kg

g/day

mg/g

Normal

2.46 ± 0.17a

66.4 ± 6.83c

16.4 ± 1.36c

3.9 ± 0.79c

Control

1.01 ± 0.11b

133.2 ± 5.87b

17.8 ± 1.58c

15.6 ± 2.31b

M1

50

0.93 ± 0.15b

140.5 ± 7.66b

21.3 ± 2.17b

18.6 ± 2.46a,b

100

0.85 ± 0.13b

153.9 ± 6.05a

26.8 ± 1.90a

20.5 ± 1.47a

Values represent mean ± S.D. (n=9). Values sharing the same column superscript letter are not significantly different from each other (P < 0.05) by Duncan’s multiple range test

Download Excel Table
Table 9. Serum leptin and insulin levels in the normal and diet-induced obesity rats fed with M1 for 2 weeks

Treatment

Dose

Leptin

Insulin

mg/kg

mg/dL

Normal

8.76 ± 0.47c

3.56 ± 0.19b

Control

26.25 ± 6.43a

4.16 ± 0.30a

M1

50

24.83 ± 3.29a

4.06 ± 0.28a

100

16.55 ± 3.10b

3.97 ± 0.21a,b

Values represent mean ± S.D. (n=9). Values sharing the same column superscript letter are not significantly different from each other (P < 0.05) by Duncan’s multiple range test

Download Excel Table

Identification of compounds

To find a key functional anti-hyperlipidemic compound in M1, the properties were compared with the reference substance after separation using the HPLC (data not shown). The results demonstrated fucosterol as the key functional compound (Fig. 1).

fas-22-0-27-g1
Fig. 1. Structure of fucosterol
Download Original Figure

Discussion

Hyperlipidemia, obesity, and diabetes mellitus are chronic diseases associated with serious complications that may consequently increase the risk of atherosclerosis. Thus, regulating the serum cholesterol levels is important, as increased serum levels of TC and LDL-C are the significant determinants in the development of atherosclerosis (Jeong et al., 2010).

In the present study, we investigated the effects of the alginate residue extracted from sea tangle on the serum lipid profile of hyperlipidemic and diet-induced obesity rats. The results demonstrated that M1 administration in the hyperlipidemic rats significantly decreased the serum TC, TG, and LDL-C levels. Previous studies have reported the hypolipidemic effects of edible seaweeds, dietary fiber, plant sterols, and herbal extracts, as indicated by decreased serum TC, TG, and LDL-C levels on rats (Nigon et al., 2001; Ara et al., 2002; Yamada et al., 2003; Megalli et al., 2005; Jeong et al., 2010). According to these studies, lowering serum TC and LDL-C levels plays an important role in reducing the risk of developing atherosclerosis.

In addition, the diet-induced obesity rats treated with M1 reported decreased abdominal fat weight compared to the control rats. These results suggest that the M1 fraction effects obesity by reducing the abdominal fat weight in obese rats. We also investigated the total lipid, TG, and TC levels in the fecal contents of the control and diet-induced obesity rats fed with M1. The M1-treated rats reported increased fecal content of the total lipid, TG, and TC levels. This data indicated that M1 lowered the serum lipid through the increased excretion of total lipid, TG, and TC from the body. Hence, it was concluded that M1 demonstrated hypolipidemic activity in rats. Moreover, lowering the serum cholesterol level is crucial for the prevention of cardiovascular diseases (Hideomi et al., 2005). M1 treatments also exerted anti-hyperlipidemic effects by regulating the serum lipid levels in rats with induced hyperlipidemia. HPLC was performed to confirm the presence of functional components in the M1 fraction, and the identification of fucosterol in the M1 fraction was confirmed by the comparison of retention times with the reference standard. In previous studies, fucosterol, isolated from marine algae Pelvetia siliquosa, has been investigated for anti-oxidant and anti-diabetic activities (Lee et al., 2003; Lee et al., 2004). Furthermore, many studies have reported that among the serum lipids, LDL-C is the most dangerous, as the oxidation of LDL leads to its increased infiltration in the arterial walls (Aviram, 1993). Therefore, reducing the oxidation of LDL-C is essential due to the presumed involvement in the development of atherosclerotic disease.

Conclusions

Our results demonstrated that the alginate-free residue of sea tangle reduces serum levels of TC, TG, and LDL-C. These results suggest that the alginate-free residue of sea tangle contains physiologically active components, such as fucosterol, that may exert beneficial effects in the prevention of atherosclerosis.

Acknowledgements

This work was supported by the study for the establishment of the marine natural products library, funded by the National Marine Biodiversity Institute of Korea (2019M00700).

Authors’ contributions

MJY carried out the hypolipidemic activity and drafted the manuscript. GC carried out the glucose and cholesterol analysis. JML identified fucosterol as the key functional compound. SYC participated in the design of the study and helped to draft the manuscript. DSL designed the study and completed the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the study for the establishment of the marine natural products library, funded by the National Marine Biodiversity Institute of Korea (2019M00700).

Availability of data and materials

Not applicable.

Ethics approval and consent to participate

Animal experiments were performed according to the institutional guidelines for the care and the use of laboratory animals, and the protocol was approved by the Animal Ethics Committee of Kyungsung University.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

1.

Ara J, Sultana V, Qasim R, Ahmad VU. Hypolipidemic activity of seaweed from Karachi Coast. Phytother Res. 2002; 16:479-483

2.

Aviram M. Modified forms of low density lipoprotein and atherosclerosis. Atherosclerosis. 1993;98:1–9.

3.

Duhault J, Boulanger M, Beregi L, Sicot N, Bouvier F. A new type of hyperlipidemic agent comparative assay in rats. Atherosclerosis. 1976; 23:63-72

4.

Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem. 1957; 226:497-509

5.

Friedwald WT, Levy RL, Fedreicson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without was of the preparative ultracentrifuge. Clin Chem. 1972; 18:499-506.

6.

Ghule BV, Ghante MH, Saoji AN, Yeole PG. Hypolipidemic and antihyperlipidemic effects of Lagenaria siceraria Stand. Fruit extracts. Indian J Exp Biol. 2006; 44:905-909

7.

Ghule BV, Ghante MH, Saoji AN, Yeole PG. Antihyperlipidemic effect of the methanolic extract from Lagenaria siceraria Stand. Fruit in hyperlipidemic rats. J Ethnopharmacol. 2009; 124:333-337

8.

Goldstein JL, Schroot HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease 11: genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 1973; 52:1544-1568

9.

Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol. 2003; 91:7A-11A

10.

Hideomi A, Makoto K, Daniel AC, Haruka O, Takaaki H. Effect of a seaweed mixture on serum lipid level and platelet aggregation in rats. Fish Sci. 2005; 71:1160-1166

11.

Jeong BY, Cho DM, Moon SK, Pyeun JH. Quality factors and functional components in the edible seaweeds - I. Distribution on n-3 fatty acids in 10 species of seaweeds by their habitats. J Korean Soc Food Sci Nutr. 1993; 22:612-628.

12.

Jeong SC, Jeong YT, Yang BK, Islam R, Koyyalamudi SR, Pang G, Cho KY, Song CH. White button mushroom (Agaricus bisporus) lowers blood glucose and cholesterol levels in diabetic and hypercholesterolemic rats. Nutr Res. 2010; 30:49-56

13.

Kusama H, Nishiyama M, Ikeda S. Pharmacological investigation of bezafibrate a hypolopodemic agent. Effects of bezafibrate on normal and experimental hyperlipidemia in rats. Nihon Yakurigaku Zasshi. 1998; 92:175-180

14.

Lee S, Lee YS, Jung SH, Kang SS, Shin KH. Anti-oxidant activities of fucosterol from the marine algae Pelvetia siliquosa. Arch Pharm Res. 2003; 26:719-722

15.

Lee YS, Shin KH, Kim BK, Lee S. Anti-diabetic activities of fucosterol from Pelvetia siliquosa. Arch Pharm Res. 2004; 27:1120-1122

16.

Lemhadri A, Hajji L, Michel JB, Eddouks MJ. Cholesterol and triglycerides lowering activities of caraway fruits in normal and streptozotocin diabetic rats. J Ethnopharmacol. 2006; 106:321-326

17.

Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med. 1995; 332:512-521

18.

Megalli S, Aktan F, Davies NM, Roufogalis BD. Phytopreventative anti-hyperlipidemic effects of Gynostemma pentaphyllum in rats. J Pharm Pharm Sci. 2005; 8:507-515

19.

Nigon F, Serfaty-Lacrosniere C, Beucler I, Beucler I, Chauvois D, Neveu C, Giral P, Giral P, Chapman MJ, Bruckert E. Plant sterol-enriched margarine lowers plasma LDL in hyperlipidemic subjects with low cholesterol intake: effect of fibrate treatment. Clin Chem Lab Med. 2001; 39:634-640

20.

Okai Y, Higashi-okai K, Nakamura S. Identification of heterogenous antimutagenic activities in the extract of edible brown seaweeds, Laminaria japonica (Makonbu) and Undaria pinnatifida (Wakame) by the umu gene expression system in Salmonella typhimurium (TA1535/pSK1002). Mutat Res. 1993; 30:63-70

21.

Park PJ, Kim EK, Lee SJ, Park SY, Kang DS, Jung BM, Kim KS, Je HY, Ahn CB. Protective effects against H2O2-induced damage by enzymatic hydrolysates of an edible brown seaweed, sea tangle (Laminaria japonica). J Med Chem. 2009; 12:159-166.

22.

Wang Y, Tang XX, Yang Z, Yu ZM. Effect of alginic acid decomposing bacterium on the growth of Laminaria japonica (Phaephyceae). J Environ Sci. 2006; 18:543-551.

23.

Wout ZG, Pec EA, Johnston TP. Biological activity of urease formulated in Poloxamer-407 after intraperitoneal injection in the rat. J Pharm Sci. 1992; 81:626-630

24.

Yamada K, Tokunaga Y, Ikeda A, Ohkura K, Kaku-Ohkura S, Mamiya S, Lim BO, Tachibana H. Effect of dietary fiber on the lipid metabolism and immune function of aged Sprague-Dawley rats. Biosci Biotechnol Biochem. 2003; 67:429-433

Abbreviations

HDL-C

High-density lipoprotein-cholesterol

LDL-C

Low-density lipoproteincholesterol

SFE

Supercritical fluid extraction

TC

Total cholesterol

TG

Triglycerides

TSO

Trans-stilbene oxide